Pre-emptive therapy of acute graft-versus-host disease: A pilot study with antithymocyte globulin (ATG)

Research output: Contribution to journalArticle

Abstract

We have previously shown that patients at high risk of graft-versus-host disease (GVHD) and transplant-related mortality (TRM) can be identified on day +7 following an allogeneic bone marrow transplant (BMT), based on serum bilirubin and blood urea nitrogen levels. One possible approach to reduce the risk of GVHD and TRM, is pre-emptive treatment with T cell antibodies. We report a pilot study testing the feasibility of this approach in 18 high risk patients, with a median age of 41,83% of whom had advanced disease, undergoing an alternative donor BMT (family mismatched in five and unrelated in 13). The patients received three doses of rabbit antithymocyte globulin (ATG) (Thymoglobuline; Sangstat) 1.25 mg/kg on alternate days, starting at a median interval of 11 days (range 7-13) after BMT. Controls were 20 historical unrelated donor transplants (median age 35, 63% with advanced disease), with a high score from our original publication in 1999. The actuarial 1 year TRM of the ATG-treated patients was 40% compared to 60% for untreated controls (P = 0.06). Severe grade III-IV aGVHD developed in 27% of the ATG-treated patients, and in 55% of the controls (P = 0.08). This study indicates that early preemptive treatment of aGVHD in day +7 high risk patients is feasible and may lead to a reduction of aGVHD and TRM. This approach is being tested in a prospective randomized trial.

Original languageEnglish
Pages (from-to)1093-1096
Number of pages4
JournalBone Marrow Transplantation
Volume28
Issue number12
DOIs
Publication statusPublished - 2001

    Fingerprint

Keywords

  • Anti-thymocyte globulin
  • Bone marrow transplantation
  • Graft-versus-host disease

ASJC Scopus subject areas

  • Hematology
  • Transplantation

Cite this